共 50 条
- [1] Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled StudyBLOOD, 2015, 126 (23)Zelenetz, Andrew D.Robak, TadeuszCoiffier, BertrandDelgado, JulioMarlton, PaulaAdewoye, Adeboye H.Kim, YeonheeDreiling, Lyndah K.Hillmen, Peter
- [2] Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trialLANCET ONCOLOGY, 2017, 18 (03): : 297 - 311Zelenetz, Andrew D.Barrientos, Jacqueline C.Brown, Jennifer R.Coiffier, BertrandDelgado, JulioEgyed, MiklosGhia, PaoloIlles, ArpadJurczak, WojciechMarlton, PaulaMontillo, MarcoMorschhauser, FranckPristupa, Alexander S.Robak, TadeuszSharman, Jeff P.Simpson, DavidSmolej, LukasTausch, EugenAdewoye, Adeboye H.Dreiling, Lyndah K.Kim, YeonheeStilgenbauer, StephanHillmen, Peter
- [3] IDELALISIB IN COMBINATION WITH BENDAMUSTINE/RITUXIMAB IMPROVES OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY CLL: INTERIM RESULTS OF A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDYHAEMATOLOGICA, 2016, 101 : 433 - 433Hillmen, P.Ferra, C.Garcia-Marco, J.Jacob, A.Jurczak, W.Lamanna, N.MacDonald, D.Marlton, P.Mayer, J.Morchauser, F.Nathwani, A.Schuh, A.Stilgenbauer, S.Wierda, W.Ysebaert, L.Adewoye, A.Kim, Y.Zelenetz, A.Delgado, J.
- [4] A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely of idelalisib on eninhination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Salles, Gilles A.Lamanna, NicoleAmin, Bipinkumar R.Boccia, Ralph V.Gabrali, Nashat Y.Zaydan, Muhammad-All A.Wong, MichelleAdewoye, Adeboye H.Ghia, Paolo
- [5] Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final ResultsCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S220 - S221Ghia, PaoloPluta, AndrzejWach, MalgorzataLysak, DanielKozak, TomasSimkovic, MartinKaplan, PolinaKraychok, IrynaIlles, Arpadde la Serna, JavierDolan, SeanCampbell, PhilipMusuraca, GerardoJacob, AbrahamAvery, Eric J.Lee, Jae HoonWang, DenisePatel, PritiJurczak, Wojciech
- [6] ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF ASCENDHAEMATOLOGICA, 2020, 105 : 205 - 206Ghia, PaoloPluta, AndrzejWach, MalgorzataLysak, DanielKozak, TomasSimkovic, MartinKaplan, PolinaKraychok, IrynaIlles, ArpadDe la Serna, JavierDolan, SeanCampbell, PhilipMusuraca, GerardoJacob, AbrahamAvery, Eric J.Lee, Jae HoonWang, DenisePatel, PritiJurcza, Wojciech
- [7] Results of a randomized, double-blind placebo controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Barrientos, Jacqueline ClaudiaBrown, Jennifer R.Atallah, Ehab L.Coutre, StevenDe La Serna, JavierEradat, Herbert AaronFarber, Charles MichaelJanssens, AnnLoscertales, JavierPocock, ChristopherShadman, MazyarAdewoye, Adeboye H.Aiello, MariaDreiling, LyndahKim, YeonheeZelenetz, Andrew DavidStilgenbauer, Stephan
- [8] Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S280 - S281Ghia, PaoloPluta, AndrzejWach, MalgorzataLysak, DanielKozak, TomasSimkovic, MartinKaplan, PolinaKraychok, IrynaIlles, ArpadDe La Serna, JavierDolan, SeanCampbell, PhillipMusuraca, GerardoJacob, AbrahamAvery, Eric J.Lee, Jae HoonLiang, WeiPatel, PritiQuah, ChengJurczak, Wojciech
- [9] Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III studyJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)Chanan-Khan, Asher Alban AkmalCramer, PaulaDemirkan, FatihFraser, GraemeSilva, Rodrigo SantucciPylypenko, HalynaGrosicki, SebastianJanssens, AnnPristupa, AlexanderMayer, JiriDilhuydy, Marie-SarahLoscertales, JavierBartlett, Nancy L.Avigdor, AbrahamRule, SimonSun, StevenMahler, MichelleSalman, MariyaHowes, Angela J.Hallek, Michael J.
- [10] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)BLOOD, 2013, 122 (21)Furman, Richard R.Sharman, Jeff P.Coutre, Steven E.Cheson, Bruce D.Pagel, John M.Hillmen, PeterBarrientos, Jacqueline C.Zelenetz, Andrew D.Kipps, Thomas J.Flinn, IanGhia, PaoloEradat, HerbertErvin, ThomasLamanna, NicoleHallek, MichaelCoiffier, BertrandPettitt, Andrew R.Ma, ShuoStilgenbauer, StephanCramer, PaulaAiello, MariaJohnson, Dave M.Miller, Langdon L.Li, DanielJahn, Thomas M.Dansey, Roger D.O'Brien, Susan M.